KB-1387

Secukinumab

Home » Antibody » Secukinumab

Background

Secukinumab falls under the category of biologic medications, exerting its therapeutic action by specifically targeting interleukin-17A (IL-17A), a pivotal protein in the body implicated in the inflammatory cascade driving psoriasis. IL-17A, a cytokine of significance in the pathogenesis of psoriasis, orchestrates inflammation and fosters the generation of various cytokines and immune cells that actively contribute to the disease's progression. By impeding IL-17A, Secukinumab effectively mitigates inflammation, decelerates the proliferation of skin cells, and ameliorates the symptomatic manifestations of psoriasis. This multifaceted action aids in alleviating the symptoms associated with the condition.

Specifications

Catalog Number:
KB-1387
Cell Line Name:
Secukinumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
IL17A
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR (December 2017). "A Review of the Use of Secukinumab for Psoriatic Arthritis". Rheumatology and Therapy. 4 (2): 233¨C246. 2. "FDA Approves Intravenous Variant of Secukinumab for Psoriatic Arthritis, Other Arthritis Types". HCP Live. 6 October 2023.
Please enable JavaScript in your browser to complete this form.